SG11201907375VA - Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders - Google Patents

Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders

Info

Publication number
SG11201907375VA
SG11201907375VA SG11201907375VA SG11201907375VA SG11201907375VA SG 11201907375V A SG11201907375V A SG 11201907375VA SG 11201907375V A SG11201907375V A SG 11201907375VA SG 11201907375V A SG11201907375V A SG 11201907375VA SG 11201907375V A SG11201907375V A SG 11201907375VA
Authority
SG
Singapore
Prior art keywords
international
compounds
enriched extract
immunological disorders
guarulhos
Prior art date
Application number
SG11201907375VA
Other languages
English (en)
Inventor
Cristiano Ruch Werneck Guimarães
Carlos Eduardo Vitor
Lisandra Ravanelli Pessa
Romulo Dragani Reis
Alessandra Mascarello
Fernando Henrique De Souza Gama
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of SG11201907375VA publication Critical patent/SG11201907375VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/47Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/92Unsaturated compounds containing keto groups containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
SG11201907375VA 2017-02-17 2018-02-19 Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders SG11201907375VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102017003318A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
PCT/BR2018/050037 WO2018148816A2 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders

Publications (1)

Publication Number Publication Date
SG11201907375VA true SG11201907375VA (en) 2019-09-27

Family

ID=61282932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907375VA SG11201907375VA (en) 2017-02-17 2018-02-19 Plant extracts enriched with ipolamiide derivatives as immunosuppressants for treating immunological disorders

Country Status (27)

Country Link
US (1) US20200231561A1 (pl)
EP (2) EP4001270A1 (pl)
JP (2) JP7349362B2 (pl)
KR (1) KR20190121790A (pl)
CN (1) CN110475768B (pl)
AU (1) AU2018221956B2 (pl)
BR (2) BR102017003318A2 (pl)
CA (1) CA3052713A1 (pl)
CL (1) CL2019002309A1 (pl)
CO (1) CO2019008891A2 (pl)
CY (1) CY1125187T1 (pl)
DK (1) DK3583103T3 (pl)
EC (1) ECSP19058322A (pl)
ES (1) ES2909387T3 (pl)
HR (1) HRP20220377T1 (pl)
IL (1) IL268732A (pl)
LT (1) LT3583103T (pl)
MX (2) MX2019009655A (pl)
PE (1) PE20200449A1 (pl)
PL (1) PL3583103T3 (pl)
PT (1) PT3583103T (pl)
RS (1) RS63162B1 (pl)
SA (1) SA519402443B1 (pl)
SG (1) SG11201907375VA (pl)
SI (1) SI3583103T1 (pl)
WO (1) WO2018148816A2 (pl)
ZA (1) ZA201906106B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
AU651849B2 (en) * 1990-10-09 1994-08-04 Tsumura & Co. Iridoid derivatives and their use as medicines
DE19644422C2 (de) * 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1145709A1 (de) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen
AU2003224361B2 (en) * 2002-05-10 2008-01-31 Council Of Scientific And Industrial Research Hepatoprotective activity of 2'-p-Hydroxybenzoylmussaenosidic acid
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
JP2008024670A (ja) 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
BRPI0700767B8 (pt) * 2007-02-15 2021-05-25 Ache Laboratorios Farmaceuticos Sa composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo
CN103120699B (zh) * 2011-11-18 2017-04-19 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) * 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
DE102015102020A1 (de) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologisch aktives Phyto-Gemisch und seine Anwendung bei der Prävention und in einem Verfahren zur Behandlung von Effloreszenzen

Also Published As

Publication number Publication date
CN110475768A (zh) 2019-11-19
JP2020507607A (ja) 2020-03-12
PT3583103T (pt) 2022-03-25
CA3052713A1 (en) 2018-08-23
EP3583103A2 (en) 2019-12-25
US20200231561A1 (en) 2020-07-23
ES2909387T3 (es) 2022-05-06
CY1125187T1 (el) 2023-06-09
RS63162B1 (sr) 2022-05-31
JP2023061959A (ja) 2023-05-02
AU2018221956B2 (en) 2022-03-24
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
ECSP19058322A (es) 2019-10-31
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
BR112019017128A2 (pt) 2020-04-14
CN110475768B (zh) 2023-12-01
LT3583103T (lt) 2022-04-25
MX2019009655A (es) 2020-07-24
AU2018221956A1 (en) 2019-08-29
SA519402443B1 (ar) 2023-02-08
PE20200449A1 (es) 2020-02-28
AU2022201835A1 (en) 2022-04-07
RU2019129095A (ru) 2021-03-17
ZA201906106B (en) 2020-08-26
JP7349362B2 (ja) 2023-09-22
WO2018148816A3 (en) 2018-10-18
MX2022012282A (es) 2022-10-27
CL2019002309A1 (es) 2020-05-29
CO2019008891A2 (es) 2020-01-17
KR20190121790A (ko) 2019-10-28
WO2018148816A4 (en) 2019-01-03
SI3583103T1 (sl) 2022-07-29
RU2019129095A3 (pl) 2021-10-27
BR102017003318A2 (pt) 2018-10-30
PL3583103T3 (pl) 2022-08-01
DK3583103T3 (da) 2022-03-14
WO2018148816A2 (en) 2018-08-23

Similar Documents

Publication Publication Date Title
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201811706RA (en) Process for the preparation of microcapsules
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts
SG11201909606RA (en) Probiotic molecules for reducing pathogen virulence
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11202000136YA (en) Preparation comprising vonoprazan
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201901272WA (en) Mesenchymal cell-derived exosomes to treat neurological disorders
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201901374WA (en) Antibiotic compounds
SG11201805001UA (en) Method of treating influenza a
SG11201809594WA (en) Nicotine particles and compositions
SG11201811708QA (en) Process for the preparation of microcapsules
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201808856TA (en) Production of steviol glycosides in recombinant hosts
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201407934UA (en) Camsylate salt
SG11201901188VA (en) Metal powder feedstocks for additive manufacturing, and system and methods for producing the same
SG11201810075QA (en) A method for manufacturing a lead-free or low lead content brass billet and billet thus obtained
SG11201908393YA (en) Modulators of pcsk9 expression